CAN YOU IDENTIFY these new vaccine products and formulations that have recently become available? To find out, match each vaccine product formulation in Section II with its brand name and manufacturer in Section I. If a patient reports a suspected adverse event that may be associated with a vaccine, complete an event report at the Vaccine Adverse Event Reporting System website: https://vaers.hhs.gov.

Section I

_____ 1. Bexsero (GlaxoSmithKline)

_____ 2. Shingrix (GlaxoSmithKline)

_____ 3. Fluad (Seqirus Inc.)

Section II

a. influenza vaccine, adjuvanted. This inactivated influenza vaccine preparation is indicated for adults age 65 and older for immunization against influenza A and B subtypes. As an adjuvanted vaccine, this formulation is associated with a more robust immune response in older adults. This vaccine is contraindicated in patients with a history of severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

b. meningococcal group B vaccine. A new two-dose vaccine, this product is intended to provide immune protection against infection caused by Neisseria meningitidis serogroup B. It is approved for use in older children and adults ages 10 to 25. The tip caps of the prefilled syringes contain natural rubber latex, so assess patients for latex sensitivity.

c. zoster vaccine recombinant, adjuvanted. This two-dose recombinant herpes zoster (shingles) vaccine is the preferred formulation for patients age 50 and older and should be administered regardless of history of herpes zoster infection or prior receipt of the live zoster vaccine. This product requires reconstitution before I.M. administration. Once reconstituted, it should be administered immediately or given within 6 hours if stored in the refrigerator.

References available upon request.

Answers: 1b, 2c, 3a